Last reviewed · How we verify
MAFENIDE ACETATE
At a glance
| Generic name | MAFENIDE ACETATE |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 1969 |
Approved indications
Common side effects
- Pain on application or burning sensation
- Rash
- Itching
- Facial edema
- Swelling
- Hives
- Blisters
- Erythema
- Eosinophilia
- Tachypnea
- Hyperventilation
- Decrease in arterial pCO2
Serious adverse events
- Fatal hemolytic anemia with disseminated intravascular coagulation
- Bone marrow depression
- Acute attack of porphyria
- Excoriation of new skin
- Bleeding of skin
Key clinical trials
- Study of the Treatment of Burn Wounds With Antimicrobial Topical Soaks (PHASE2, PHASE3)
- Effects of Therapy With Sulfamylon® 5% Topical Solution Compared to a Historical Control Group (PHASE4)
- Patients Response to Early Switch To Oral:Osteomyelitis Study (EARLY_PHASE1)
- Safety Study of a Novel Wearable Phototherapy System for the Management of Acute Burn Wounds (NA)
- Study of Low Adherent Dressing Versus the Standard of Care for the Management of Skin Grafts Over Thermal Burns (NA)
- Vashe Wound Therapy Study (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MAFENIDE ACETATE CI brief — competitive landscape report
- MAFENIDE ACETATE updates RSS · CI watch RSS